Stem Cell Therapeutics Corp.: Dr. Alan Moore Will Present the Company's Brain and Neural Regeneration Therapy for the Treatment

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announced that Dr. Alan
Moore, President and CEO, will be presenting today at the Banff Venture Forum
2009, taking place in Banff, Alberta, October 1-2. Dr. Moore will be providing
an overview of the Company's clinical and pre-clinical stage programs, including
progress in the Phase IIb stroke trial with Drs. Steven C. Cramer of the
University of California, Irvine and Michael D. Hill of the Foothills Hospital
at the University of Calgary, as co-lead investigators; as well as its
soon-to-commence multiple sclerosis ("MS") phase II trial with prolactin, lead
by Drs. Luanne Metz and Fiona Costello of the MS Clinic at the Foothills Medical
Centre in Calgary, Alberta. 


About the Banff Venture Forum (www.banffventureforum.com): Banff Venture Forum
2009 is the premier company financing event in Canada. It will showcase early
and growth stage companies in three streams: Information Technology, Energy
Technology and Life Sciences Technology. Featured companies will be presenting
before investors from across North America with the intention of securing the
investment required to grow their businesses. 


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.